Market research
ACST.V Acasti Pharma Inc
V CAD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 2.45
- Dividend yield
- 0.0%
- Beta
- 1.22
Profile
Instrument facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA00430K8730
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 2.45
- Dividend yield
- 0.0%
- Beta
- 1.22
About
About Acasti Pharma Inc
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Research context
Acasti Pharma Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ACST.V discussion.
5 years, 6 months ago
Acasti Pharma Inc is currently in a long term uptrend where the price is trading 12.5% above its 200 day moving average.
From a valuation standpoint, the stock is 31.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 698.7.
Acasti Pharma Inc's total revenue rose by inf% to $81K since the same quarter in the previous year.
Its net income has increased by 73.3% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 55.4% to $-4M since the same quarter in the previous year.
Based on the above factors, Acasti Pharma Inc gets an overall score of 5/5.